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NEOPLASIA
Plag1 and Plagl2 are oncogenes that induce acute myeloid leukemia
in cooperation with Cbfb-MYH11
Sean F. Landrette, Ya-Huei Kuo, Karen Hensen, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Paola N. Perrat,
Wim J. M. Van de Ven, Ruud Delwel, and Lucio H. Castilla
Recurrent chromosomal rearrangements
are associated with the development of
acute myeloid leukemia (AML). The fre-
quent inversion of chromosome 16 cre-
ates the CBFB-MYH11 fusion gene that
encodes the fusion protein CBF-SMMHC.
This fusion protein inhibits the core-
binding factor (CBF), resulting in a block
of hematopoietic differentiation, and in-
duces leukemia upon the acquisition of
additional mutations. A recent genetic
screen identified Plag1 and Plagl2 as
CBF-SMMHC candidate cooperating pro-
teins. In this study, we demonstrate that
Plag1 and Plagl2 independently cooper-
ate with CBF-SMMHC in vivo to effi-
ciently trigger leukemia with short la-
tency in the mouse. In addition, Plag1 and
Plagl2 increased proliferation by induc-
ing G1 to S transition that resulted in the
expansion of hematopoietic progenitors
and increased cell renewal in vitro. Fi-
nally, PLAG1 and PLAGL2 expression was
increased in 20% of human AML samples.
Interestingly, PLAGL2 was preferentially
increased in samples with chromosome
16 inversion, suggesting that PLAG1 and
PLAGL2 may also contribute to human
AML. Overall, this study shows that Plag1
and Plagl2 are novel leukemia oncogenes
that act by expanding hematopoietic pro-
genitors expressing CbF-SMMHC.
(Blood. 2005;105:2900-2907)
© 2005 by The American Society of Hematology
Introduction
The core-binding factor (CBF) is the most common target of
chromosomal translocations in acute myeloid leukemia (AML).
Frequent rearrangements affecting CBF include the chromosome
16 inversion inv(16)(p13;q22) [hereafter inv(16)] and the transloca-
tion t(8;21)(q22;q22).1 CBF is a heterodimeric transcription factor
composed of 1 of 3 DNA-binding  subunits (encoded by RUNX1,
RUNX2, and RUNX3) and a non-DNA binding  subunit (encoded
by CBFB). In hematopoiesis, the RUNX1:CBF complex is a key
regulator of lymphoid and myeloid differentiation. For example,
studies using knock-out mice demonstrated that embryonic defini-
tive hematopoiesis is defective in the absence of Cbf or Runx1.2-5
In adult hematopoiesis, Runx1 knockouts show deficient differentia-
tion of T cells, B cells, and myeloid cells.6
The inv(16) breaks and joins CBFB with the smooth muscle
myosin heavy chain (MYH11) gene, creating the CBFB-MYH11
fusion gene, which encodes the CBF-SMMHC fusion protein.7
Interestingly, Cbfb/MYH11 knock-in embryos expressing this fusion
protein lack definitive hematopoiesis, as shown in Cbfb and Runx1
knock-out embryos, thus indicating that Cbf-SMMHC is a
dominant inhibitor of CBF function.8 Normal lymphoid and
myeloid differentiation was also impaired in hematopoietic stem
cells from Cbfb/MYH11 knock-in chimeras expressing Cbf-
SMMHC. In addition, these mice developed AML after induction
of additional mutations.9 However, little is known about the genes
and pathways that cooperate with CBF-SMMHC in leukemogen-
esis. We have recently performed a genetic screen, by means of
retroviral insertional mutagenesis (RIM), in Cbfb/MYH11 knock-in
chimeras to identify genes that could synergize with Cbf-
SMMHC in leukemia development.10 The study identified
retroviral insertions at the Plag1 locus in as many as 40% of the
samples and at the Plagl2 locus in 10% of the samples.
Interestingly, the proviral insertions mapped upstream of the
translation-start site, thus suggesting that up-regulation of these
genes may contribute to AML.
The PLAG family is composed of 3 members (PLAG1,
PLAGL1/LOT1/ZAC1, and PLAGL2) with highly conserved
structure and function.11 These proteins are transcription factors
that include a C-terminal trans-activation domain preceded by 7
C2H2 zinc fingers with DNA binding function. Genetic studies
have associated PLAG1 with benign tumors harboring 8q12
translocations, including pleomorphic adenomas of the salivary
gland, lipoblastomas, and hepatoblastomas.12-14 PLAGL2 has not
been previously associated with human cancer, but it has been
reported to have similar DNA-binding affinity to the Plag1
consensus sequence and to induce proliferation in NIH-3T3 cells.15
Conversely, PLAGL1 seems to function as a tumor suppressor
protein that is found mutated in breast and pituitary tumors16,17 and
that regulates apoptosis and G1 cell cycle arrest.18
In the present study we tested whether Plag1 and PLAGL2 are
oncogenes in AML using a combination of in vivo and in vitro
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assays. We found that these transcription factors are specifically
up-regulated in RIM-induced leukemic samples with retroviral
insertions within these loci. To functionally validate their role in
leukemogenesis we used a bone marrow transduction assay fol-
lowed by transplantation (tBMT). Coexpression of either Plag1 or
PLAGL2 and Cbfb-MYH11 efficiently induced AML in 100% of
recipient mice with a latency of 3 to 12 weeks. Furthermore, Plag1
or PLAGL2 induced expansion of hematopoietic progenitors and
increased proliferation by inducing G1 to S transition in vitro.
Importantly, PLAG1 and PLAGL2 are overexpressed in 20% of
human AML. Among these, PLAGL2 is preferentially overex-
pressed in samples carrying inv(16). These results are in concor-
dance with our in vivo studies in the mouse and highlight PLAG1
and PLAGL2 oncogenic function in human leukemia.
Materials and methods
Reverse transcriptase and quantitative PCR (qPCR) analyses
RT and qPCR of murine samples. RNA was extracted with guanidium
thiocyanate followed by centrifugation in cesium chloride solution or with Trizol
(Invitrogen, Carlsbad CA) according to the manufacturer’s protocol. First-stand
cDNA was generated by using 2 g RNA, 1 U Superscript-2 reverse transcrip-
tase (RT; Invitrogen), and 0.1 g oligo dT primer in a 20-L reaction. Each
polymerase chain reaction (PCR) included 1L cDNA, 1L 10 mM primers, 1
L 10 mM deoxyribonucleoside triphosphates (dNTPs), 5 L 10 buffer, 1 U
Taq Polymerase (Fisher Scientific, Pittsburgh PA). PCR conditions included a
2-minute step at 95°C followed by a 30-cycle amplification (each with a
30-second denaturing step at 95°C, a 30-second annealing step at 56°C, and a
30-second extension step at 72°C). SYBR Green PCR Master Mix (Applied
Biosystems, Foster City, CA) was used for qPCR according to the manufacturer’s
instructions. Plag1 primers were mP1 1 (GGTTCACTCCTTCTCTCA-
CACG) and mP1 2 (TGAGTAGCCATGTGCCTTTGTA). Plagl2 primers
were mPL2 1 (TATAGGCACATGGCCACCCACT) and mPl2 2 (TGAC-
GACGGTATCCCAGCTTT). The long terminal repeat (LTR) primer was LTR1
(CTCTTGCTGTTGCATCGGACT). Igf2 primers were mIgf2-1 (AGTC-
CGAGAGGGACGTGTCTAC) and mIgf2-2 (CGTCCCGCGGACTGTCTC).
Actb (-actin) primers were b-actinF1(CGAGGCCCAGAGCAAGAGAG) and
b-actinR1 (CGGTTGGCCTTAGGGTTCAG). QPCR was performed in an ABI
PRISM 7000 sequence detection system (Applied Biosystems). Samples were
normalized to beta-actin expression levels, and relative values were determined
by the standard curve method.
qPCR of human samples. Bone marrow samples from 162 patients
with AML at diagnosis (classified according to the French-American-
British nomenclature; Table 1) and 6 healthy volunteers were obtained after
informed consent. Approval was obtained from the Erasmus Medical
Center institutional review board for these studies. Blasts from patients with
AML and mononucleated fractions from normal bone marrow specimens
were isolated by Ficoll-Hypaque (Nygaard, Oslo, Norway) centrifugation
and then cryopreserved. After thawing, cells were washed with Hanks
Balanced Salt Solution (HBSS) and further processed for RNA isolation.
AML samples treated according to this procedure usually contain more than
90% blasts after thawing. Total RNA was extracted with guanidium
thiocyanate followed by centrifugation in cesium chloride solution. RNA (1
g) was transcribed into cDNA by using Superscript (Life Technologies,
Merelbeke, Belgium) and random hexamers in a 40-L reaction, under
standard conditions. The qPCR amplification was performed in an ABI
PRISM 7900 HT Sequence Detector, using 12.5 L SYBR Green PCR
Master Mix (PE Biosystems, Nieuwekerk a/d IJssel, The Netherlands), 2
L (1/20th aliquot) cDNA, 2.5 pmol primer mix (Life Technologies), and
10 L water. The PCR conditions included 2 minutes at 50°C and 10
minutes at 95°C followed by 45 cycles of amplification (each with a
15-second denaturation step at 95°C and a 1-minute annealing/extension
step at 60°C). The PLAG1 primers were hP1Taq1 (ACACAGGAGAGAG-
GCCCTACA) and hP1Taq2 (ATGAGTAGCCATGTGCC TTTGT); the
PLAGL2 primers were hPL2Taq1 (CACTGTGGCAAGGCTTTTGC) and
hPL2Taq2 (GATGGTCCTTGCGGTGAAACAT). qPCR for normalization
control was carried as described previously.19
To determine PLAG1 and PLAGL2 relative expression levels, the
average Ct (threshold cycle) values from duplicate readings were normal-
ized for endogenous reference (dCt  Ct target Ct PBGD) and compared
with a calibrator using the “delta-delta Ct method” (Ct  Ct Sample 
Ct Calibrator). As calibrator we used the average Ct value of PLAG1 or
PLAGL2 in the 6 CD34 healthy volunteer samples. Using the Ct value,
relative expression was calculated (2Ct).
Retroviral production
The Plag1 cDNA was cloned from testis RNA by using PFU polymerase
(Stratagene, La Jolla, CA) and primers mP1FlF (GATAATCTCGAGAC-
CATGGATT ACAAGGATGACGACGACGATAAGGCCACTGTCAT-
TCCTGGTGAT) and mP1F1R (GAATGAGAAGCGGCCGCACTA-
CTGAAAAGCTTGATGGA). The PLAGL2 cDNA was cloned by using
primers hPL2FF (GATAATCTCGAGACCATGGA TTACAAGGATGAC-
GACGACGATAAGACCACATTTTTCACCAGCGT) and hPL2FR
(GAATGAGAAGCGGCCGCACTACTGGAATGCTTGGTGGA). The
PCR amplicons were cut with Xho1 and Not1 and cloned into pMSCVire-
sEGFP(MIG).20 Phoenix packaging cells (generously provided by Gary
Nolan, Stanford University, CA) were cotransfected with 2 g retroviral
constructs, 2 g 	-Eco packaging plasmid with Effectene reagent
(Quiagen, Valencia CA) according to manufacturer’s protocol. Retrovirus
supernatants were taken at 24, 48, and 72 hours and titered in 3T3 cells by
fluorescence-activated cell sorting (FACS) analysis for green fluorescent
protein (GFP).
Bone marrow transduction and transplantation (tBMT)
Cbfb-MYH11 expression was induced in a Cbfb56M/ conditional knock-in
mouse model recently generated in our laboratory with the use of the
Cre-Lox system. Its characterization will be published elsewhere. Cbfb-
MYH11 was induced by using the Mx1Cre transgenic mouse.21 Briefly,
Cbfb56M//Mx1Cre double transgenics or wild-type control mice were
injected with 3 doses of polyinosinic-polycytidylic acid (pI-pC; Sigma, St
Table 1. Clinical characteristics of the AML samples
Characteristics Number
Gender
Male 77
Female 85
Age, median (range), y 42.3 (15.2-60.8)
Age groups
Younger than 35 51
35-50 62
50 and older 49
FAB
M0 4
M1 39
M2 33
M3 13
M4 32
M5 36
M6 2
Unclassified 3
Cytogenetic risk group
Favorable 34
inv(16) 12
t(8;21) 11
t(15;17) 11
Intermediate 111
Unfavorable 17
WBC count, median (range), 109/L 29.8 (0.3-263)
Blast count, median (range), % 66 (0-98)
FAB indicates French-American-British; WBC, white blood count.
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Louis, MO) at 3 weeks of age, and cells were harvested 6 days after
treatment with 150 mg/kg 5-fluorouracil. Double transgenic bone marrow
cells consistently rendered more than 90% of Cre-mediated Cbfb-MYH11
induction. Cells were spin-infected twice with retrovirus supernatant.
Following infection, 5  105 to 1  106 bone marrow cells were trans-
planted into 4- to 6-week-old sublethally irradiated (650 rads [6.5 Gy])
129SvEv wild-type mice intravenously. Mice were under daily observation
for early signs of leukemia. These signs included limited motility, pale
paws, and dehydration. At first signs of illness, peripheral blood was
analyzed for cell number and morphology for the presence of immature
cells. FACS analysis of peripheral blood was performed by using antibodies
to cell-surface markers Gr-1, CD11b, B220, CD3, Ter119, and c-kit
(Pharmingen, San Diego CA). Leukemic cells were harvested from the
bone marrow or spleen of affected mice in RPMI 1640 (Invitrogen,
Carlsbad, CA) and 20% fetal bovine serum (FBS; Invitrogen), and
single-cell suspension aliquots of 1  106 cells were transplanted intrave-
nously in sublethally irradiated 4- to 6-week-old 129Sv/Ev recipients.
Southern blot analysis
Southern blot analysis was performed following standard protocols.
Briefly, spleen DNA from leukemic and control mice was cut with
HindIII (to identify viral insertions in sample) separated in a 0.8%
agarose gel and transferred onto Hybond-XL nylon membrane (Amer-
sham-Pharmacia Biotech, Buckinghamshire, England). The 800-base
pair (bp) GFP probe was an EcoRI/NcoI fragment from MIG. Hybridiza-
tions were performed overnight at 45°C in formamide solution (Hy-
brisol-I; Serologicals, Norcross, GA).
Methylcellulose colony-forming assay and cell-cycle analysis
129SvEv bone marrow cells expressing Cbfb-SMMHC were harvested 6
days after treatment with 150 mg/kg 5-fluorouracil, spin-infected with 2
rounds of retrovirus supernatant (either MIG, MIG-Plag1, or MIG-
PLAGL2), and sorted for GFP expression. GFP-positive cells (1  104)
were plated (in triplicate) in methylcellulose supplemented with interleu-
kin 3 (IL3), IL6, and stem cell factor (SCF; Methocult 3534). Colonies
were counted 7 days after plating and analyzed by FACS and cytospin.
Remaining cells were recovered and 1  104 cells were serially replated
for 3 rounds. For cell-cycle analysis, sorted cells were fixed in 70%
ice-cold ethanol, stained with 50 g/mL propidium iodide (Sigma), and
analyzed by FACS.
Cytology and histology analysis
Morphology analysis of peripheral blood cells was carried out on modified
Wright-Giemsa–stained smears and cytospins. Histology analysis was
conducted on sections from paraffin-embedded blocks and stained with
Hematoxylin and Eosin (Histoserv, Gaithersburg, MD). Images were taken
using a Zeiss Axioskop 40 microscope (Carl Zeiss, Jena, Germany) with
40  or 100  (under Zeiss Immersol 518N oil) lenses, or a Zeiss Stemi
2000-C stereoscope at 6.5 magnification. The images were acquired with
a Zeiss AxioCam MRc camera and MR-Green acquisition software.
Results
Retroviral insertions induce Plag1 and Plagl2 overexpression
in leukemic samples expressing Cbfb-MYH11
Our recent RIM study identified 8 retroviral insertions at the Plag1
locus and 2 at the Plagl2 locus in Cbfb-MYH11–associated
leukemia samples. These results suggested that the transcription
factors may play a critical role in inv(16) AML.10 To determine the
precise location of retroviral insertions in the Plag1 locus, we
analyzed the Plag1 gene structure in the mouse genome. The
sequence of the 5
 Plag1 cDNA was cloned from embryo RNA
(embryonic day 14.5) by using a combination of RT-PCR and
5
-rapid amplification of cDNA ends (RACE; GenBank accession
no. AY574219). Analysis of this sequence using the public mouse
genome database (http://genome.ucsc.edu) confirmed that the 8
Plag1-associated RIM retroviral insertions were located in its
introns 1 and 2, upstream of the translation start codon in exon 4,
and in the transcriptional orientation10 (Figure 1A). Notably, these
introns are also involved in the breakpoints of 8q21-associated
translocations in salivary gland adenomas.22 Considering that the
retroviral insertions mapped upstream of Plag1 and Plagl2 transla-
tional start site and in the same transcriptional orientation, we
reasoned that these insertions may up-regulate Plag1 and Plagl2
transcription. Therefore, we analyzed Plag1 and Plagl2 expression
in normal and RIM-AML samples. The Plag1 transcript was not
detected in mouse hematopoietic tissues by RT-PCR (Figure 1B).
Furthermore, expression was not detected in a panel of 10
RIM-AML samples with retroviral insertions in other loci (Figure
1B, sample V65; data not shown). Conversely, Plag1 was ex-
pressed in all samples with retroviral insertions in the Plag1 locus.
Finally, since these AML samples were induced in Cbfb/MYH11
chimeras, Cbfb-MYH11 expression was confirmed in leukemia
samples by RT-PCR (Figure 1B, middle panel).
In humans, PLAGL2 is expressed during embryogenesis and not
Figure 1. Plag1 and PLAGL2 are overexpressed in RIM-AML samples. (A) Representation of Plag1-RIM insertions (V62, Vc6, V84, V85, VC4, V61, VC2, V89). Thin arrows
indicate location of retroviral insertions and direction of LTR-transcription. Triangles indicate regions of chromosomal breakpoints in pleomorphic adenomas.22 Boxes indicate
exons, including untranslated (u) and translated () regions, and alternatively spliced exon 2b (z). (B) RT-PCR analysis of Plag1 (top panel), Cbfb-MYH11(middle panel), and
Actb (-actin) (bottom panel), including whole embryo day 14.5 (E14.5), testis (te), bone marrow (bm), hematopoietic progenitor-enriched bone marrow (bmp; bone marrow 6
days after 5-fluorouracil treatment), spleen (sp), peripheral blood white blood cells (pb), Plag1-associated RIM-AML samples (V62, Vc6, V85, Vc4, Vc2, V89, and V84), Vc6
transplant (Vc6T), Plagl2-associated AML sample (V65), and 0.1 ng Plag1 plasmid control (c). (C) Representation of Plagl2-RIM insertions (Vc1 and V65). Arrows indicate
location of retroviral insertions and direction of LTR-transcription. Boxes indicate exons, including untranslated (u) and translated () regions. (D) RT-PCR analysis of Plagl2
(top panel), Plagl2 transcribed from viral LTR (middle panel), and Actb (bottom panel); including hematopoietic tissues, Plag1-associated RIM-AML samples (V62, Vc6, V85,
Vc4, Vc2, V89, and V84), Plagl2 RIM-AML sample V65, and a representative RIM-AML sample with no viral insertion near Plag1 or Plagl2 (V68). (E) Quantitative PCR analysis
of Plagl2, using Plagl2 specific primers, in normal and leukemic samples. Expression levels were normalized to Actb and shown relative to sample E14.5 (E14.5  1). Error
bars indicate standard errors from duplicate experiments.
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detected in adult tissues.11 In the mouse, however, Plagl2 is
detected in several tissues, showing higher expression in lung,
spleen, and testes.23 The RIM-AML samples Vc1 and V65 included
retroviral insertions in Plagl2 intron 1, in the same transcription
orientation and upstream of its translation start codon (Figure 1C).
Plagl2 expression was detected in all normal tissues analyzed
(Figure 1D, top panel, lanes 1-6). The RIM-AML samples analyzed
also expressed Plagl2 (Figure 1D, top panel, lanes 7-4), with higher
levels in the Plagl2-associated sample V65 (RNA from sample Vc1
was not available). Similar analyses that used LTR-forward and
Plagl2-reverse primers identified a strong band only in sample V65
(Figure 1D, middle panel), confirming that the increase in Plagl2
expression was transcribed from the retroviral LTR. Furthermore,
increased Plagl2 relative expression levels (RELs) were confirmed
by qPCR using Plagl2-specific primers (Figure 1E). Therefore,
upstream retroviral insertions up-regulated Plag1 and Plagl2
transcription in Plag-associated leukemic samples.
Plag1 and Plagl2 cooperate with Cbfb-MYH11
to induce leukemia
The Plag1 and Plagl2 overexpression in mouse RIM-AML samples
suggests that these zinc finger transcription factors may participate
in leukemogenesis. Therefore, we tested whether Cbfb-MYH11 and
Plag1 or Plagl2 coexpression is sufficient to trigger AML in the
mouse by using a tBMT assay (described in “Materials and
methods”). All mice that received transplants with bone marrow
cells expressing Cbfb-MYH11/MIG-Plag1 (n 22) or Cbfb-MYH11/
MIG-PLAGL2 (n  19) readily developed leukemia 3 to 12 weeks
after transplantation (Figure 2A). Control groups remained healthy
Figure 2. Plag1 and PLAGL2 cooperate with Cbfb-MYH11 to
induce AML in mice. (A) Kaplan-Meier survival curve of mice that
received transplants with bone marrow cells expressing: Cbfb-
MYH11 and MIG-Plag1 (thick dashed line), Cbfb-MYH11 and
MIG-PLAGL2 (thick solid line), Cbfb-MYH11 and MIG (thin solid
line), MIG-Plag1 (thin dashed line), or MIG-PLAGL2 (dotted-
dashed line). (B) Representation of the MIG-Plag1/L2 provirus.
The LTRs (‹), coding sequence for Plag1/L2 (sequence encoding
Plag1 or PLAGL2) and GFP (open arrows), internal ribosome
entry site (IRES; `), probe (thick line), HindIII restriction sites (H),
genomic (thin line) and viral (double thin line) sequences, are
detailed. (C) Representative Southern blot analysis of transplanta-
tion of leukemic cells. DNA from PLAG-associated primary leuke-
mia (lanes 1, 6, 9, 11), secondary transplanted leukemias (lanes
2, 3, 7, 8, 10, 12, 13), and tertiary transplanted leukemias (lanes 4
and 5) were probed with the retroviral GFP sequence. Thin arrows
indicate which primary leukemic cells were used for secondary
and tertiary transplants. Asterisk shows a band that represents the
clonal expansion of a population of leukemic cells that became
predominant in mice that receive transplants. The expected
molecular weight of expected fragments (in kb) is indicated at the
left. (D) Pathologic characteristics of leukemic cells. Wright-
Giemsa staining of ( 10 magnification) normal (panel i) and
leukemic (panel iii) bone marrow, normal (panel ii) and leukemic
spleen (panel iv), and representative blastlike (panel v) and
monocytic-like (panel vi) cells ( 100 magnification). Note area
with lymphoid (A), red (B), megakaryocytes (C), and leukemic (D)
cells.
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up to 5 months (experimental end point), including mice that
received transplants with cells expressing Cbfb-MYH11/MIG
(n  24), MIG-Plag1 (n  17), or MIG-PLAGL2 (n  17).
To confirm that these cells were leukemic, bone marrow cells
from affected mice (Plag1, n  10; PLAGL2, n  9) were
transplanted into sublethally irradiated secondary recipients (2
transplants per donor cell population). In all cases, the leukemic
cells were readily transplantable with an average disease onset
of 4 weeks.
As Plag1 and PLAGL2 are expressed from the MIG-LTR
(Figure 2B), we were able to examine the clonality of disease by
Southern blot analysis using primary, secondary, and tertiary
leukemic samples. Multiple bands were detected in most primary
leukemic samples (Figure 2C, lanes 1, 6, 9, and 11), while
secondary (Figure 2C, lanes 2, 3, 7, 8, 10, 12, and 13) and tertiary
(Figure 2C, lanes 3-5) transplants frequently displayed enrichment
of subclones underrepresented in the primary transplant (note
asterisks). These data reveal that Plag1 and PLAGL2 efficiently
cooperate with Cbfb-MYH11 to induce AML in mice. In addition,
the short latency and oligoclonality of disease is consistent with the
hypothesis that leukemia may rise from few genetic alterations.
Leukemic mice exhibited an increase of immature cells and a
decrease of red blood cells and megakaryocytes in bone marrow
(Figure 2D, panels i and iii). Likewise, spleens were consistently
enlarged (with spleen weight of 601.5  234.7 mg for Plag1, and
197  106.8 mg for PLAGL2) with an altered architecture and
evident invasion of leukemic cells (Figure 2D, panels ii and iv).
Leukemic cells were progressively predominant in peripheral
blood (Plag1  23.5  106, range 7.3  106 to 74.4  106 cells/
mL; PLAGL2  12.5  106, range 0.3  106 to 61.7  106 cells/
mL), including blastlike and monocytic-like cells (Figure 2D,
panels v-vi). Occasionally, enlargement of liver resulting from
focal infiltrations of leukemic cells was also observed. However,
enlargement of the thymus and lymph nodes was not observed
(data not shown), indicating a nonlymphoid disease.
We characterized the leukemic cells by FACS analysis. The
predominant cells in peripheral blood were c-kit and Lin (Lin:
CD3, Gr1, B220, Ter119, Mac1; Figure 3). Furthermore, the
leukemic cells were consistently GFP, confirming the presence of
the provirus (Figure 3). Finally, Cbfb-MYH11 and either Plag1 or
PLAGL2 expression in leukemic cells was confirmed by RT-PCR
(data not shown).
Taken together, the morphology and FACS analysis data
indicate that these leukemic cells are predominantly blastlike and
monocytic-like cells and confirm that they express Plag1 and
Plagl2. Finally, the leukemic cells resemble Cbfb-MYH11–
associated leukemic cells previously described,9,10 supporting the
idea that Cbf-SMMHC directs the phenotypic characteristics of
leukemic cells.
Plag1 and PLAGL2 expand hematopoietic progenitors
in Cbfb-MYH11–expressing cells by increasing G1
to S phase transition of cell cycle
To further understand the role of Plag1 and Plagl2 in AML
development, in vitro differentiation assays were performed in
GFP-sorted bone marrow progenitors expressing Cbfb-MYH11 and
either MIG-Plag1, MIG-PLAGL2, or MIG. At day 7, the number of
Plag1- and PLAGL2-expressing colonies increased significantly
(Figure 4A, P1). In addition, Plag1 and PLAGL2 colonies were
predominantly compact and large when compared with diffuse
colonies in controls, suggesting an increased progenitor prolifera-
tion (Figure 4B). Furthermore, cytology analysis revealed that
colonies expressing Plag1 or PLAGL2 included predominantly
immature blasts when compared with MIG control colonies (Figure
4C). This enrichment for immature forms suggests that Plag1 and
PLAGL2 selectively expanded Cbfb-MYH11 differentiation-
blocked progenitors.
To assess the effect of Plag1 and PLAGL2 on the renewal
capacity of progenitors, 104 cells from day 7 pooled colonies were
serially replated. In contrast to MIG controls, MIG-Plag1 and
MIG-PLAGL2 transduced cells exhibited a marked increase in
replating potential (Figure 4A, P2-P3). As Plag1 and PLAGL2
seemed to expand progenitors, we next assessed their effect on
cell-cycle progression. Bone marrow cells expressing Cbfb-MYH11
were sorted after infection with MIG-Plag1, MIG-PLAGL2, or
MIG and analyzed with the use of propidium iodine staining by
FACS. Notably, Plag1 and PLAGL2 induced entry into S phase and
reduced the number of cells in G0/G1 phase (Figure 4D). The
increase of cells in S phase was also confirmed by bromodeoxyuri-
dine (BRDU) incorporation (data not shown). Overall, these data
indicate that Plag1 and Plagl2 stimulate proliferation and renewal
of hematopoietic progenitors expressing CbFb-MYHII.
PLAG1 and PLAGL2 regulate gene expression by binding to
the same DNA consensus site.24 The insulin growth factor 2 gene
(IGF2) harbors 8 PLAG binding sites in its promoter 3 and is
up-regulated in cell lines ectopically expressing PLAG1 as well as
in salivary gland tumors with PLAG1-associated transloca-
tions.15,24,25 In addition, AML samples frequently show loss of
imprinting at the IGF2 locus associated with IGF2 overexpres-
sion.26 Therefore, it is possible that PLAG1 and PLAGL2 could
Figure 3. Peripheral blood leukemic cells are Lin/c-kit and GFP. Representa-
tive examples of peripheral blood leukemic cell FACS analysis. FACS analysis of
lineage markers (Gr1, B220, CD3, Ter119, and Mac1) and GFP, versus hematopoietic
progenitor marker (c-kit) for wild-type (left column) and leukemic cells expressing
either Cbfb-MYH11/Plag1 (middle column) or Cbfb-MYH11/PLAGL2 (right column).
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expand hematopoietic precursors via the IGF2 pathway to induce
AML in cooperation with Cbf-SMMHC. To test this hypothesis,
we assessed Igf2 levels in GFP-sorted bone marrow cells and
leukemic samples expressing Plag1, PLAGL2, or without expres-
sion of these genes by qPCR. Igf2 RELs were increased by Plag1
and PLAGL2 in bone marrow (Figure 4E; data not shown).
However, RELs were not increased in leukemia samples when
compared with non-Plag1– or -PLAGL2–induced AMLs. These
results indicate that Igf2 transcripts are up-regulated by Plag1 and
PLAGL2 in hematopoietic progenitors, but that Plag1 and PLAGL2
do not maintain increased levels of Igf2 in leukemic progression.
PLAG1 and PLAGL2 are overexpressed in human AML
AML is a heterogeneous disorder with regard to both morphology
and chromosomal aberrations detected in the leukemic cells.
Currently, AML is classified according to pretreatment karyotype
and treatment outcome. For example, cytogenetic groups with
inv(16)/t(16;16), t(15;17), and t(8;21) define an AML subset with
increased survival (favorable outcome).
To investigate whether PLAG1 or PLAGL2 could also play a
role in human AML, we asked whether PLAG1 and PLAGL2 are
up-regulated in human AML samples. The RELs of PLAG1 and
PLAGL2 were analyzed in a panel of 162 human primary AML
samples by qPCR. The REL values were normalized to PBGD
expression and compared with expression levels in normal CD34
bone marrow cells. The panel was divided into 4 cytogenetic
groups: 12 samples with inv(16)(p13q22)/t(16;16) expressing
CBFB-MYH11, 11 samples with t(15:17), 11 samples with t(8:21),
and 128 samples without these translocations. The characteristics
of the AML samples are detailed in Table 1.
Overall, PLAGL2 was overexpressed in 15% of the samples.
Strikingly, higher RELs were associated with inv(16) than with the
other cytogenetic subgroups (Figure 5A). The association between
PLAGL2 and CBFb-MYH11 was highlighted, as no other cytoge-
netic change was common in inv(16) samples (Table 2). In
addition, PLAGL2 expression was significantly higher in t(8:21)
and t(15:17) subgroups (with P  .01 and P  .05, respectively;
2-tailed paired t test) when compared with samples without these 3
chromosomal rearrangements or inv(16).
The RELs of PLAG1 transcript were also significantly increased
1.4- to 2.4-fold (P  .0001; 2-tailed paired t test) in 5% (8 of 162)
of the samples analyzed (Figure 5B). The overexpression did not
correlate with a distinct cytogenetic subgroup, suggesting that
PLAG1 may cooperate with other mutations associated with AML.
PLAG1 overexpression has been associated in tumors with chromo-
some 8 polyploidy,14,29 and trisomy of chromosome 8 is a frequent
rearrangement in human AML. However, we found no correlation
between trisomy 8 and increased PLAG1 expression in this AML
panel (trisomy 8 REL  0.14  0.13, n  18; disomy 8
REL  0.24  0.44, n  144). These data reveal that PLAG1 and
PLAGL2 expression is deregulated in human AML. Furthermore,
PLAGL2 overexpression strongly correlates with inv(16) AML.
Discussion
AML arises from the uncontrolled clonal expansion of hematopoi-
etic progenitor cells that have acquired (at least) 2 types of genetic
alterations. These cooperating mutations have been classified as
Figure 4. Plag1 and PLAGL2 increase proliferation of hematopoietic progenitor in vitro by inducing entry into S phase. (A) Serial replating (P1 to P3) of 104
Cbfb-MYH11–expressing bone marrow cells infected with MIG (), MIG-Plag1 (f), or MIG-PLAGL2 (u) and cultured in methylcellulose culture for 7 days. (B) Representative
images of colony morphology at day 7. (C) Lineage distribution colony-forming units (CFUs) from P1 analyzed by cytospin of individual colonies. Colony types are indicated as
granulocytic (G; p), monocytic (M; `), granulocytic and monocytic (GM; f), mix (u), and blast (z). (D) Cell-cycle analysis of sorted bone marrow cells expressing Cbfb-MYH11
and MIG-Plag1 (gray line), MIG-PLAGL2 (dotted black line), or MIG (solid black line) and stained with propidium iodine. (E) The Igf2 RELs determined by quantitative PCR in
E14.5 total embryo (lane 1), MIG wild-type bone marrow (lane 2), MIG-PLAGL2 wild-type bone marrow (lane 3), MIG Cbfb-MYH11 bone marrow cells (lane 4), MIG-PLAGL2
Cbfb-MYH11 bone marrow (lane 5), Plag1/Cbfb-MYH11 leukemias (lanes 6-8), PLAGL2/Cbfb-MYH11 leukemias (lanes 9-11), and leukemias not overexpressing Plag1 or
PLAGL2.12-15 Values were normalized to Actb expression levels. Error bars indicate standard error from triplicate experiments.
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“class-I” mutations, conferring hematopoietic progenitor expan-
sion (such as increase in proliferation, cell survival, or self-renewal
potential), and “class-II” mutations, inducing impairment of hema-
topoietic differentiation.30 Previously, we demonstrated that expres-
sion of the inv(16)-associated Cbfb-MYH11 fusion gene (a class-II
mutation) impairs hematopoietic differentiation in the mouse, and
that this effect is required for leukemogenesis.9 Our genetic study
identified Plag1 and Plagl2 as class-I candidate genes for Cbfb-
MYH11–associated leukemogenesis in the mouse.9 The current
study demonstrates that up-regulation of Plag1 and PLAGL2 is a
class-I mutation that induces AML in cooperation with
Cbf-SMMHC.
Plag1 and Plagl2 were specifically overexpressed in RIM-AML
samples with retroviral insertions at these loci, confirming the
genetic data previously published and further implicating these
genes in mouse leukemia. Using a tBMT assay, we demonstrate
that both transcription factors can independently cooperate with
Cbf-SMMHC to induce AML in 3 to 12 weeks with 100%
penetrance. Mice consistently display expansion of immature cells
and infiltration into peripheral blood, spleen, and liver, whereas
lymph nodes and thymus remain unaffected. The leukemic cells in
peripheral blood morphologically appear as blastlike and monocytic-
like cells and are predominantly Lin/c-kit. Interestingly, al-
though the leukemic cells have a myeloid morphology, their
immunophenotype suggests that this population contains blastlike
cells stalled at an early stage of differentiation. This phenotype is
similar to the AML observed in Cbfb/MYH11 knock-in mice treated
with chemical or retroviral mutagens. Taken together, these studies
suggest that Cbfb-MYH11, and not the cooperating gene(s), deter-
mines the phenotype of the disease.
Consistent with the oligoclonal and aggressive course of
disease, coexpression of Cbfb-MYH11 and Plag1 or Plagl2 may be
sufficient to trigger AML in the mouse. Alternatively, as the tBMT
assays require insertion of the retroviral vector in the hematopoietic
progenitor’s genome, it is possible that a third hit could be required
for AML development. We show that Plag1 and Plagl2 oncogenic
function is associated with expansion of hematopoietic progenitors
expressing Cbf-SMMHC. This is evident in the blastlike colony
morphology, the increase of blast cells in these colonies, the
increase of cells entering into S and G2/M phases, and the expanded
replating potential. Interestingly, these results are similar to the
mitogenic effect that Plag1 or Plagl2 overexpression provides
NIH-3T3 cells.15
The effect of Plag1 and Plagl2 in leukemogenesis is similar to
that of other class-I genes mutated in human inv(16) AML,
including activating (oncogenic) mutations in KRAS and FLT3.31,32
For example, expression of activated Flt3 or Kras alone cannot
induce AML in the mouse,33-35 but Flt3 efficiently induces AML in
cooperation with promyelocytic leukemia–retinoic acid receptor 
(PML-RAR).36 Conversely, activated Kras or Flt3 alone induces a
myeloproliferative-like disease, while Plag1- and Plagl2-express-
ing mice remain healthy. Also, the in vitro expansion of hematopoi-
etic precursors observed on Plag1 or PLAGL2 expression was not
observed in oncogenic Kras cultures.34 These differences may
indicate that distinct pathways are involved.
Previous studies have shown that PLAG1 and PLAGL2 up-
regulate IGF2.15,24 In addition, AML samples frequently show loss
of imprinting at the IGF2 locus associated with IGF2 overexpres-
sion.26 Surprisingly, our study shows that Plag1 and PLAGL2
induce moderate Igf2 transcript levels in bone marrow cells, but
that this increase is not maintained in leukemic samples. These
results suggest that the Plag transcription factors may affect an
Igf2-independent pathway in leukemogenesis or play a role in
initiation but not maintenance of leukemia.
We find PLAGL2 expression preferentially induced in human
AML samples with inv(16), supporting our findings using the
mouse model. Interestingly, PLAGL2 was also significantly in-
duced in t(8;21)–and t(15;17)–associated AML samples, suggest-
ing that PLAGL2 may also induce AML in cooperation with other
fusion genes. This is the first study implicating PLAGL2 in human
cancer and demonstrating that both Plag1 and PLAGL2 function as
oncogenes in vivo. It will be, therefore, interesting to examine
PLAGL2 function in other cancers. Considering the in vivo effect
of Plag1 and Plagl2 in Cbfb-MYH11–dependent AML in mice and
increased PLAG1 and PLAGL2 levels in human AML without
inv(16) cytogenetics, it will be important to test whether these
transcription factors can also induce AML in cooperation with
other class-II fusion genes in vivo. Interesting examples could
Table 2. Cytogenetics of inv(16) AML samples
ID Cytogenetics
1 46, XY, inv(16)(p13;q22)
2 46, XY, inv(16)(p13;q22)
3 46, XY, inv(16)(p13;q22)[37]/47,id,  8[2]/47,id,  21[4]
4 46, XY, inv(16)(p13;q22)
5 46, XY, t(16;16)(p13;q22)
6 46, XX, inv(16)(p13;q22)
7 46, XY, inv(16)(p13;q22)
8 46, XX, inv(16)(15%)/47,XX,inv(16),  22 (85%)
9 46, XX, inv(16)(p13;q22)
10 46, XX, inv(16)(p13;q22)
11 46, XX, inv(16)(p13;q22)
12 46, XX, inv(16)(p13;q22)[8]/47,idem,  8[12]
Figure 5. Quantitative PCR analysis of PLAG1 and PLAGL2 in a panel of 162
human AML samples. PLAGL2 (A) and PLAG1 (B) RELs. Samples are clustered in
4 cytogenetic groups: samples showing inv(16)(p13;q22), t(15;17), t(8;21), and
samples without these rearrangements (other). Within each group, samples are
ordered by increased PLAGL2 RELs. RELs represent the average of duplicate values
and are compared with the value of 6 healthy CD34 bone marrow samples.
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include transgenic mice models for AML1-ETO and PML-
RAR.37-39 Finally, the finding that PLAG1 and PLAGL2 zinc
finger proteins participate in AML development implicates novel
pathways in leukemogenesis and may provide additional targets in
the design of improved therapies.
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